| human | Q5 |
| P2287 | CRIStin ID | 23378 |
| P2671 | Google Knowledge Graph ID | /g/11f0zkr_fb |
| P269 | IdRef ID | 070342806 |
| P213 | ISNI | 0000000358024569 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 073240214 |
| P496 | ORCID iD | 0000-0002-8441-3093 |
| P214 | VIAF ID | 123145970056432250786 |
| P166 | award received | Order of St. Olav | Q94345 |
| P27 | country of citizenship | Norway | Q20 |
| P108 | employer | University of Oslo | Q486156 |
| Diakonhjemmet Hospital | Q11965600 | ||
| P734 | family name | Kvien | Q37221015 |
| Kvien | Q37221015 | ||
| Kvien | Q37221015 | ||
| P101 | field of work | rheumatology | Q327657 |
| P735 | given name | Tore | Q1548096 |
| Tore | Q1548096 | ||
| Kristian | Q12794332 | ||
| Kristian | Q12794332 | ||
| P106 | occupation | professor | Q121594 |
| researcher | Q1650915 | ||
| P21 | sex or gender | male | Q6581097 |
| Q56506042 | 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative |
| Q34130671 | 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative |
| Q34818729 | 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations |
| Q48049806 | 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis |
| Q38782336 | 2016 update of the EULAR recommendations for the management of early arthritis |
| Q43062337 | A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment |
| Q24609382 | A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
| Q40374563 | A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. |
| Q57506449 | A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes |
| Q53504370 | A comparison of agreement and sensitivity to change between AIMS2 and a short form of AIMS2 (AIMS2-SF) in more than 1,000 rheumatoid arthritis patients. |
| Q69209855 | A functional study of purified CD4+ and CD8+ cells isolated from synovial fluid of patients with rheumatoid arthritis and other arthritides |
| Q95800720 | A good year for European rheumatology |
| Q36757050 | A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients |
| Q41977463 | A hospital-based observational cohort study exploring pain and biomarkers in patients with hand osteoarthritis in Norway: The Nor-Hand protocol |
| Q37887735 | A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. |
| Q53090514 | A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. |
| Q35548924 | A population study of factors associated with general practitioner consultation for non-inflammatory musculoskeletal pain |
| Q27015782 | A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) |
| Q41215059 | A study of the effect of rheumatoid synovial fluid on proliferation and IL-2 production by total mononuclear cells and purified CD4+ cells of synovial fluid and peripheral blood |
| Q35637012 | ASAS/EULAR recommendations for the management of ankylosing spondylitis |
| Q82854967 | ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis |
| Q50714333 | Abdominal discomfort in patients with rheumatoid arthritis is associated with physical and mental function, self-reported disease activity, and use of anti-inflammatory medication. |
| Q74083664 | Acanthamoeba polyphaga in rheumatoid arthritis: possibility for a chronic infection |
| Q69911830 | Acetylsalicylic acid and juvenile rheumatoid Arthritis. Effect of dosage interval on the serum salicylic acid level |
| Q39995419 | Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study |
| Q89851592 | Achievement of remission in two early rheumatoid arthritis cohorts implementing different treat-to-target strategies |
| Q35554972 | Activity limitations and participation restrictions in women with hand osteoarthritis: patients' descriptions and associations between dimensions of functioning |
| Q72609624 | Acute sarcoid arthritis: occurrence, seasonal onset, clinical features and outcome |
| Q35637990 | Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study |
| Q33830219 | Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study |
| Q37210194 | Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study |
| Q57169361 | American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials |
| Q35047250 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials |
| Q37886853 | Amplification of plasmid and chromosome chlamydia dna in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies |
| Q38222328 | An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). |
| Q82414520 | Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores |
| Q84291445 | Annals of the Rheumatic Diseases: an update |
| Q41908716 | Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate |
| Q37350853 | Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study |
| Q70606465 | Assessment methods of disease activity in juvenile rheumatoid arthritis--evaluated in a prednisolone/placebo double-blind study |
| Q90215037 | Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry |
| Q46368513 | Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases |
| Q53102540 | Association analysis of the CCL3L1 copy number locus by paralogue ratio test in Norwegian rheumatoid arthritis patients and healthy controls. |
| Q43715894 | Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand |
| Q43500734 | Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis |
| Q36265758 | Association of Chest Pain and Risk of Cardiovascular Disease with Coronary Atherosclerosis in Patients with Inflammatory Joint Diseases |
| Q36356750 | Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients |
| Q89367922 | Associations Between Cardiorespiratory Fitness and Arterial Stiffness in Ankylosing Spondylitis: A Cross-sectional Study |
| Q47782073 | Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients |
| Q92432115 | Associations Between Radiographic and Ultrasound-Detected Features in Hand Osteoarthritis and Local Pressure Pain Thresholds |
| Q34683913 | Associations between APOE genotypes and disease susceptibility, joint damage and lipid levels in patients with rheumatoid arthritis |
| Q51488438 | Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. |
| Q36171863 | Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study |
| Q92670804 | Associations between ultrasound-detected synovitis, pain and function in interphalangeal and thumb base osteoarthritis: Data from the Nor-Hand study |
| Q40885129 | Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis |
| Q68765945 | Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study |
| Q72770658 | Autologous Mixed Lymphocyte Reactions in Patients with Rheumatoid Arthritis and Juvenile Rheumatoid Arthritis: Both Non-T Cells and in-Vivo-Activated T Cells Can Act as Stimulator Cells |
| Q68873467 | Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study |
| Q58621582 | Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and O |
| Q56973858 | Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries |
| Q83196225 | Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs |
| Q92606092 | Biomarkers of cardiovascular risk across phenotypes of osteoarthritis |
| Q27021115 | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
| Q30904816 | Body mass index and progressive hand osteoarthritis: data from the Oslo hand osteoarthritis cohort |
| Q84579959 | Bone erosions at the distal ulna detected by ultrasonography are associated with structural damage assessed by conventional radiography and MRI: a study of patients with recent onset rheumatoid arthritis |
| Q74479801 | Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years |
| Q73574433 | Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register |
| Q36171809 | Bone mineral density in patients with hand osteoarthritis compared to population controls and patients with rheumatoid arthritis |
| Q35549109 | Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls |
| Q57224319 | CIITA gene variants are associated with rheumatoid arthritis in Scandinavian populations |
| Q39026806 | CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up |
| Q88122320 | Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register |
| Q37584844 | Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis |
| Q83029024 | Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis |
| Q81238830 | Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis |
| Q35953503 | Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis |
| Q38621541 | Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis |
| Q91595713 | Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? |
| Q33868310 | Cardiovascular disease risk profiles in inflammatory joint disease entities |
| Q46487876 | Carotid plaque characteristics and disease activity in rheumatoid arthritis |
| Q83164458 | Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression |
| Q52864698 | Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. |
| Q84999575 | Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies |
| Q40582804 | Changes in self-efficacy and health status over 5 years: a longitudinal observational study of 306 patients with rheumatoid arthritis |
| Q47920262 | Characteristics of rheumatoid arthritis patients with self-reported sicca symptoms: evaluation of medical, salivary and oral parameters |
| Q43428017 | Chlamydia pneumoniae as a trigger of reactive arthritis |
| Q60774597 | Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study |
| Q57134005 | Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes |
| Q35551169 | Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Regis |
| Q91116734 | Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar |
| Q26753120 | Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease |
| Q43630815 | Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study |
| Q41915669 | Combination therapy in rheumatoid arthritis |
| Q93384218 | Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study |
| Q91685172 | Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis |
| Q59329016 | Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries |
| Q57830826 | Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-mod |
| Q60054288 | Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
| Q51522257 | Comparison of features by MRI and radiographs of the interphalangeal finger joints in patients with hand osteoarthritis. |
| Q68166053 | Comparison of synovectomy and no synovectomy in patients with juvenile rheumatoid arthritis. A 24-month controlled study |
| Q53270415 | Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. |
| Q44429710 | Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population |
| Q28138338 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group |
| Q84172541 | Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis |
| Q43492645 | Comparison of work disability and health-related quality of life between males and females with rheumatoid arthritis below the age of 45 years |
| Q35557840 | Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis |
| Q33655026 | Concurrent evaluation of data quality, reliability and validity of the Australian/Canadian Osteoarthritis Hand Index and the Functional Index for Hand Osteoarthritis |
| Q36677277 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| Q35638676 | Consensus statement on the use of rituximab in patients with rheumatoid arthritis |
| Q48054849 | Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases |
| Q34207133 | Consequences of handling missing data for treatment response in osteoarthritis: a simulation study |
| Q97590393 | Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities |
| Q46116182 | Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway |
| Q66938198 | Contraceptive advice to puerperal women. Does it have any effect? |
| Q35638127 | Controlling the obesity epidemic is important for maintaining musculoskeletal health |
| Q95730608 | Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis |
| Q51016307 | Correlates of functional disability in early rheumatoid arthritis: a cross-sectional study of 706 patients in four European countries. |
| Q52004662 | Correlates of patients' global assessment of arthritis impact. A 2-year study of 216 patients with RA. |
| Q39838867 | Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up |
| Q33770765 | Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis |
| Q39793055 | Cost-effectiveness analyses of elective orthopaedic surgical procedures in patients with inflammatory arthropathies |
| Q41601731 | Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies |
| Q92178523 | Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies |
| Q43266411 | Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis |
| Q34427742 | Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible |
| Q39362174 | Cross-sectional and longitudinal associations between radiographic features and measures of pain and physical function in hand osteoarthritis |
| Q45010244 | Current challenges in rheumatology |
| Q34113970 | Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis |
| Q45792169 | Current practice and barriers to the management of sexual issues in rheumatology: results of a survey of health professionals |
| Q44183395 | Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. |
| Q44197816 | Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors |
| Q59335170 | DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs |
| Q39791823 | Daily health status registration (patient diary) in patients with rheumatoid arthritis: a comparison between personal digital assistant and paper-pencil format |
| Q30614235 | Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis |
| Q36246062 | Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID) |
| Q34210394 | Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index |
| Q47258434 | Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis |
| Q72761017 | Detection of T-lymphocyte subpopulation in the peripheral blood and the synovium of patients with rheumatoid arthritis and juvenile rheumatoid arthritis using monoclonal antibodies |
| Q47782082 | Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study |
| Q39295708 | Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity |
| Q36809347 | Development and preliminary validation of the pancreatic cancer disease impact score |
| Q35605474 | Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology |
| Q36245940 | Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach |
| Q70464138 | Diagnostic criteria of rheumatoid arthritis in children. Proposed criteria for controlled clinical studies |
| Q47212009 | Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis |
| Q41273559 | Differences and similarities in rheumatology specialty training programmes across European countries |
| Q53072320 | Differences in utility and other disease severity levels in patients with rheumatoid arthritis from three European countries. |
| Q31135066 | Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMA |
| Q47295468 | Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases |
| Q39019342 | Disease Characteristics and Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-year Followup Study |
| Q35552444 | Disease activity and health status in rheumatoid arthritis: a case-control comparison between Norway and Lithuania |
| Q85316673 | Disease activity and left ventricular structure in patients with rheumatoid arthritis |
| Q50144849 | Disease activity and severity in patients with rheumatoid arthritis: relations to socioeconomic inequality |
| Q86639902 | Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study |
| Q40715496 | Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis |
| Q54249759 | Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. |
| Q48396514 | Disease impact of hand OA compared with hip, knee and generalized disease in specialist rheumatology health care |
| Q35645689 | Disease modification in rheumatoid arthritis with special reference to cyclosporin A |
| Q56966389 | Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists |
| Q36932298 | Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists |
| Q42604682 | Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis |
| Q83194491 | Distribution of joint involvement in women with hand osteoarthritis and associations between joint counts and patient-reported outcome measures |
| Q59822850 | Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical t |
| Q38667206 | Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study |
| Q36830635 | Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs |
| Q57120832 | Does the weather really matter? A cohort study of influences of weather and solar conditions on daily variations of joint pain in patients with rheumatoid arthritis |
| Q53476202 | Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. |
| Q36749766 | Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation |
| Q92827458 | Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution |
| Q99576032 | Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration |
| Q41917441 | Drug therapy in arthrosis |
| Q38155886 | Drug-free gel containing ultra-deformable phospholipid vesicles (TDT 064) as topical therapy for the treatment of pain associated with osteoarthritis: a review of clinical efficacy and safety |
| Q91327000 | EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology |
| Q39043111 | EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis |
| Q27026582 | EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria |
| Q33505914 | EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis |
| Q35636525 | EULAR expects further development in 2006. |
| Q33595690 | EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology |
| Q30244903 | EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update |
| Q35896648 | EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis |
| Q95336137 | EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update |
| Q34110066 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs |
| Q26859134 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update |
| Q40305889 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update |
| Q41949374 | EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees |
| Q35177998 | EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic |
| Q38779077 | EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures |
| Q37369605 | EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. |
| Q53761469 | EXXELERATE: a negative trial with importance for clinical practice. |
| Q46454542 | Early prediction of increased arterial stiffness in patients with chronic inflammation: a 15-year followup study of 108 patients with rheumatoid arthritis |
| Q36792775 | Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study |
| Q34530587 | Effect of high-intensity statin treatment in rheumatoid arthritis: a case with possible coronary atheroma regression and progression of rheumatoid valve degeneration |
| Q44204800 | Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease |
| Q35071057 | Effectiveness and cost-effectiveness of comprehensive rehabilitation programs |
| Q49041027 | Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis |
| Q47882851 | Effectiveness of an Integrated Multidisciplinary Osteoarthritis Outpatient Program versus Outpatient Clinic as Usual: A Randomized Controlled Trial |
| Q44376103 | Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration |
| Q82891072 | Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA |
| Q33742961 | Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register |
| Q37085666 | Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study |
| Q31046441 | Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration |
| Q35159567 | Effects of rheumatoid arthritis on bone |
| Q36930638 | Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis |
| Q52225534 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. |
| Q34277511 | Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot study |
| Q50060320 | Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply |
| Q37210207 | Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study |
| Q48416663 | Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative |
| Q44037479 | Epidemiological aspects of rheumatoid arthritis: the sex ratio |
| Q35780338 | Epidemiology and burden of illness of rheumatoid arthritis |
| Q77749254 | Epidemiology of disability in rheumatoid arthritis |
| Q42587652 | Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration |
| Q42349139 | Erratum to: Rheumatology training experience across Europe: analysis of core competences |
| Q35637985 | Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison |
| Q38661777 | European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update |
| Q37939700 | European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies |
| Q80167290 | European rheumatology is advancing |
| Q35638087 | Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis |
| Q57307068 | Evidence for PTPN22 R620W Polymorphism As the Sole Common Risk Variant for Rheumatoid Arthritis in the 1p13.2 Region |
| Q37710906 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search |
| Q38492012 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update |
| Q37085249 | Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists |
| Q39765685 | Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness? |
| Q89890463 | Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis |
| Q69351577 | Expression of activation markers on CD4+ and CD8+ cells from synovial fluid, synovial tissue, and peripheral blood of patients with inflammatory arthritides |
| Q46816592 | FCRL3 -169C/C genotype is associated with anti-citrullinated protein antibody-positive rheumatoid arthritis and with radiographic progression |
| Q60774653 | Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures |
| Q40812521 | Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries |
| Q92771511 | Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis |
| Q57299625 | Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project |
| Q83365996 | Fertility in women with chronic inflammatory arthritides |
| Q48304573 | Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative |
| Q30974307 | First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach |
| Q64959313 | First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register. |
| Q53107015 | Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. |
| Q92262711 | Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study |
| Q54447376 | Frequency of temporomandibular joint osteoarthritis and related symptoms in a hand osteoarthritis cohort. |
| Q46436416 | GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. |
| Q39295277 | Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis |
| Q97678232 | Get a grip on factors related to grip strength in persons with hand osteoarthritis: Results from the Nor-Hand study |
| Q69976639 | Gold sodium thiomalate and D-penicillamine. A controlled, comparative study in patients with pauciarticular and polyarticular juvenile rheumatoid arthritis |
| Q90211266 | Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases |
| Q47894454 | HLA-C alleles confer risk for anti-citrullinated peptide antibody-positive rheumatoid arthritis independent of HLA-DRB1 alleles |
| Q36392382 | Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss |
| Q35553275 | Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50-70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study |
| Q34064076 | Hand joint space narrowing and osteophytes are associated with magnetic resonance imaging-defined knee cartilage thickness and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative |
| Q37857540 | Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score |
| Q34798292 | Hand, hip and knee osteoarthritis in a Norwegian population-based study--the MUST protocol |
| Q38132963 | Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). |
| Q49139128 | Health status and perception of pain: a comparative study between female patients with hand osteoarthritis and rheumatoid arthritis |
| Q48151392 | Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register |
| Q78139428 | Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls |
| Q35553676 | Health status of patients with ankylosing spondylitis: a comparison with the general population |
| Q89012959 | Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls |
| Q31138492 | Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data |
| Q37876108 | Helicobacter pylori--a trigger of reactive arthritis? |
| Q51752129 | High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. |
| Q39932883 | High disease activity is a predictor of cortical hand bone loss in post-menopausal patients with established rheumatoid arthritis: a 5-year multicentre longitudinal study |
| Q35148638 | High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis |
| Q33899815 | Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries |
| Q81375944 | How important is collaboration between orthopedic surgeons and rheumatologists for optimizing the management of joint disease? |
| Q68830149 | IL-6 in synovial fluids, plasma and supernatants from cultured cells of patients with rheumatoid arthritis and other inflammatory arthritides |
| Q84972080 | Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis |
| Q81508883 | Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis |
| Q37172804 | Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group |
| Q92785328 | Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis |
| Q81463237 | Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions |
| Q46027578 | Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. |
| Q54083111 | Improved cost-effectiveness ratio with a patient self-adjusted naproxen dosing regimen in osteoarthritis treatment. |
| Q43733225 | Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group |
| Q52659242 | Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program. |
| Q91047102 | Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? |
| Q51110688 | Incidence of clinically important 10-year health status and disease activity levels in population-based cohorts with rheumatoid arthritis. |
| Q38517238 | Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry |
| Q30860792 | Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis |
| Q36304492 | Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. |
| Q48217999 | Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis |
| Q43432105 | Indications for testing of sexually transmitted Chlamydia trachomatis infections |
| Q44191676 | Inequities in access to biologic and synthetic DMARDs across 46 European countries |
| Q51652663 | Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial |
| Q34213779 | Interaction analysis between HLA-DRB1 shared epitope alleles and MHC class II transactivator CIITA gene with regard to risk of rheumatoid arthritis |
| Q57307060 | Interferon regulatory factor 5 gene polymorphism confers risk to several rheumatic diseases and correlates with expression of alternative thymic transcripts |
| Q91047154 | Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor |
| Q53342780 | Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. |
| Q36183828 | Introducing RMD Open |
| Q35954634 | Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study |
| Q73769577 | Involvement and satisfaction: a Norwegian study of health care among 1,024 patients with rheumatoid arthritis and 1,509 patients with chronic noninflammatory musculoskeletal pain |
| Q35554758 | Is rheumatoid arthritis disappearing? |
| Q84335976 | Is rheumatoid arthritis really getting less severe? |
| Q30750448 | Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study |
| Q45447873 | It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. |
| Q33287486 | Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis |
| Q47332025 | Large molecular size EDTA-resistant complexes containing S100A12, ERAC, in serum during inflammatory conditions |
| Q43903873 | Leflunomide--a new disease modifying anti-rheumatic agent |
| Q39890573 | Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. |
| Q51005631 | Life events, psychosocial factors, and demographic variables in early rheumatoid arthritis: relations to one-year changes in functional disability. |
| Q39863525 | Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study |
| Q35551644 | Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension |
| Q91570458 | Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial |
| Q64945484 | Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. |
| Q39371943 | Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study |
| Q37869927 | Lower level of synovial fluid interferon-gamma in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis |
| Q39131957 | MRI findings predict radiographic progression and development of erosions in hand osteoarthritis |
| Q84973311 | MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression |
| Q81549985 | Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression |
| Q39040238 | Mapping the Effect of Psoriatic Arthritis Using the International Classification of Functioning, Disability and Health |
| Q36942633 | Measuring disability and quality of life in established rheumatoid arthritis |
| Q46565317 | Medical prophylaxis and treatment of steroid induced osteoporosis |
| Q53118313 | Metabolic profiling of synovial tissue shows altered glucose and choline metabolism in rheumatoid arthritis samples. |
| Q33369386 | Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis |
| Q36171771 | Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? |
| Q69252902 | Mitogen-induced interleukin 2 and gamma interferon production by CD4+ and CD8+ cells of patients with inflammatory arthritides. A comparison between cells from synovial fluid and peripheral blood |
| Q51125184 | Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. |
| Q72314578 | Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis |
| Q33735306 | Multidisciplinary and multifaceted outpatient management of patients with osteoarthritis: protocol for a randomised, controlled trial |
| Q56966479 | Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t |
| Q51999062 | Musculoskeletal pain and quality of life in patients with noninflammatory joint pain compared to rheumatoid arthritis: a population survey. |
| Q30866962 | NOR-DMARD data management: implementation of data capture from electronic health records. |
| Q48175744 | NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study |
| Q53859169 | Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. |
| Q33553973 | Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q89124311 | New-generation JAK inhibitors: how selective can they be? |
| Q86042374 | No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs |
| Q43049027 | No improvement in a pilot study of tai chi exercise in rheumatoid arthritis |
| Q58795531 | Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent |
| Q80848335 | Norwegian version of the Canadian Occupational Performance Measure in patients with hand osteoarthritis: validity, responsiveness, and feasibility |
| Q57537036 | Novel genetic association of theVTCN1region with rheumatoid arthritis |
| Q33373508 | Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up |
| Q55338290 | Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. |
| Q70515652 | Oral gold (auranofin) in juvenile rheumatoid arthritis: a 48-week phase II study |
| Q51676956 | Orthopaedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health-related quality of life. |
| Q57148284 | Osteoporosis in patients with rheumatoid arthritis: Tip of the iceberg?: LETTER TO THE EDITOR |
| Q35097529 | Outcomes from the Patient Perspective Workshop at OMERACT 6. |
| Q35954648 | Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis |
| Q48694066 | Pain catastrophizing is strongly associated with subjective outcomes, but not with inflammatory assessments in rheumatoid arthritis patients |
| Q44813935 | Parity in patients with chronic inflammatory arthritides childless at time of diagnosis |
| Q40201322 | Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study |
| Q36183841 | Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology |
| Q30482468 | Patient perspective in outcome assessments--perceptions or something more? |
| Q52841954 | Patient satisfaction with nursing consultations in a rheumatology outpatient clinic: a 21-month randomised controlled trial in patients with inflammatory arthritides. |
| Q43494109 | Patient-reported quality of care for osteoarthritis: development and testing of the osteoarthritis quality indicator questionnaire |
| Q43825661 | Patients with inflammatory arthropathies undergo feet surgery later in the disease course than hand surgery. |
| Q39838852 | Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria |
| Q47677653 | Pattern of joint involvement and other disease characteristics in 634 patients with arthritis of less than 16 weeks' duration |
| Q51703128 | Perceived influence of health status on sexual activity in RA patients: associations with demographic and disease-related variables. |
| Q33413162 | Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline |
| Q35554807 | Performance of health status measures with a pen based personal digital assistant |
| Q36674075 | Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis |
| Q45172441 | Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures |
| Q81752151 | Performance of the Norwegian version of AUSCAN--a disease-specific measure of hand osteoarthritis |
| Q48313586 | Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to other patient-reported outcomes in a register of patients with rheumatoid arthritis |
| Q91448548 | Peripheral and Central Sensitization of Pain in Individuals With Hand Osteoarthritis and Associations With Self-Reported Pain Severity |
| Q35093046 | Pharmacotherapy for regional musculoskeletal pain |
| Q61912472 | Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients |
| Q24242813 | Physiotherapy interventions for ankylosing spondylitis |
| Q24245684 | Physiotherapy interventions for ankylosing spondylitis |
| Q38777496 | Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative |
| Q34687675 | Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis |
| Q37453998 | Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort |
| Q84489870 | Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry |
| Q93384223 | Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study |
| Q39958466 | Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients |
| Q39608539 | Prediction of cardiovascular events in patients with ankylosing spondylitis and psoriatic arthritis: role of lipoproteins in a high-risk population |
| Q93192331 | Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models |
| Q37885269 | Prediction of diagnosis in acute and subacute oligoarthritis of unknown origin |
| Q43300360 | Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study |
| Q38852492 | Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis |
| Q41134158 | Predictors of Fatigue in Rheumatoid Arthritis Patients in Remission or in a Low Disease Activity State |
| Q90571015 | Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol |
| Q74714748 | Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority |
| Q44389747 | Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth |
| Q78108626 | Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology |
| Q35555889 | Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent |
| Q53158014 | Prevalence and burden of osteoarthritis: results from a population survey in Norway. |
| Q37403116 | Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study |
| Q75248150 | Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients |
| Q77291739 | Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold |
| Q37578140 | Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design |
| Q42647972 | Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated pr |
| Q90147232 | Psychometric performance of the PAncreatic CAncer disease impact (PACADI) score |
| Q36290134 | Quality of life in rheumatoid arthritis |
| Q51752631 | Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. |
| Q35554362 | Quantitative ultrasound and bone mineral density: discriminatory ability in patients with rheumatoid arthritis and controls with and without vertebral deformities |
| Q47985306 | Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study |
| Q42099452 | Radiographic temporomandibular joint abnormalities in patients with juvenile chronic arthritis during a controlled study of sodium aurothiomalate and D-penicillamine |
| Q37888036 | Reactive arthritis: a favorable 2 year course and outcome, independent of triggering agent and HLA-B27. |
| Q28251791 | Reactive arthritis: incidence, triggering agents and clinical presentation |
| Q37578137 | Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria |
| Q73385968 | Recent onset arthritis in the elderly: a 5 year longitudinal observational study |
| Q73363954 | Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register |
| Q39720453 | Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial |
| Q44061249 | Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study |
| Q72068458 | Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis |
| Q39737972 | Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting |
| Q81000154 | Reliability of the Canadian Occupational Performance Measure in patients with ankylosing spondylitis |
| Q35953576 | Reliability of the ICF Core Set for rheumatoid arthritis |
| Q53084090 | Reliability, sensitivity to change and feasibility of three radiographic scoring methods for hand osteoarthritis. |
| Q85085364 | Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort |
| Q47432586 | Remission in psoriatic arthritis-where are we now? |
| Q83355833 | Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study |
| Q47230525 | Repeated measures in rheumatoid arthritis reduced the required sample size in a two-armed clinical trial |
| Q91581562 | Reply to "Achievement of remission according to different treat-to-target strategies: comment on the article by Norvang et al." |
| Q38542032 | Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies |
| Q33369384 | Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations |
| Q57169471 | Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations |
| Q81710018 | Reproducibility and sensitivity to change of 5 methods for scoring hand radiographic damage in patients with rheumatoid arthritis |
| Q36759845 | Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paper |
| Q89929436 | Response to 'Does inflammation predict radiographic progression in hand osteoarthritis?' by Li et al |
| Q46958299 | Response to expression of concern regarding VIGOR study |
| Q48268444 | Response to: 'Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis' by Chevreau et al. |
| Q47649531 | Response to: 'Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis' by Boer et al. |
| Q88556060 | Response to: 'Disease activity and left ventricular systolic function in rheumatoid arthritis' by Giollo et al |
| Q53212272 | Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis. |
| Q73473028 | Results from controlled clinical trials: how relevant for clinical practice? |
| Q91006953 | Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA |
| Q44022783 | Rheumatic diseases and sexuality: Disease impact and self-management strategies |
| Q80546467 | Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994-2004 |
| Q42687089 | Rheumatology care: Involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in patients with rheumatoid arthritis and ankylosing spondylitis |
| Q37280698 | Rheumatology training experience across Europe: analysis of core competences |
| Q31154802 | Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration |
| Q53487037 | Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. |
| Q40086682 | Role of erosions typical of rheumatoid arthritis in the 2010 ACR/EULAR rheumatoid arthritis classification criteria: results from a very early arthritis cohort |
| Q30667212 | Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study |
| Q51043783 | Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study. |
| Q102331190 | Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long-term Results of Two Phase III Randomized Controlled Trials |
| Q91155909 | Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE |
| Q59790112 | Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study |
| Q83878514 | Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria |
| Q35553780 | Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables |
| Q51967604 | Self-efficacy and health status in rheumatoid arthritis: a two-year longitudinal observational study. |
| Q51558923 | Self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in a very early arthritis cohort. |
| Q79843008 | Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity |
| Q81820607 | Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents |
| Q35555243 | Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis |
| Q39592868 | Severity of musculoskeletal pain: relations to socioeconomic inequality |
| Q69641759 | Sex education in schools. Experience from teaching in 20 senior high school classes in Oslo |
| Q39865593 | Short-time in vitro and in vivo precision of direct digital X-ray radiogrammetry |
| Q85030793 | Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study |
| Q35549969 | Sicca symptoms and secondary Sjögren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables |
| Q35548697 | Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis |
| Q39672360 | Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes |
| Q48329421 | Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies |
| Q41916986 | Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis--evaluated in a randomized, parallel 50-week clinical trial |
| Q43685328 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine |
| Q38763440 | Smoking and alcohol use are associated with structural and inflammatory hand osteoarthritis features |
| Q56966110 | Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration |
| Q91545306 | Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients |
| Q57779993 | Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis |
| Q72231863 | Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study |
| Q35993667 | Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study |
| Q30612910 | Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study |
| Q38787053 | Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial |
| Q92570655 | Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis |
| Q37884932 | Synovial fluid and serum antibodies against Chlamydia in different forms of arthritis: intra-articular IgA production in Chlamydia sexually acquired reactive arthritis |
| Q39711494 | Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state |
| Q50763760 | Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype? |
| Q87610276 | Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention |
| Q93363307 | Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study |
| Q95523031 | Tenosynovitis in rheumatoid arthritis patients on biologic treatment: involvement and sensitivity to change compared to joint inflammation |
| Q83942421 | Tenosynovitis of the extensor carpi ulnaris tendon predicts erosive progression in early rheumatoid arthritis |
| Q43519179 | Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis |
| Q37578135 | Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers |
| Q36753659 | Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. |
| Q50061682 | Thank you and goodbye! |
| Q57244812 | The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I |
| Q34802740 | The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report |
| Q39876932 | The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis |
| Q53761432 | The AUSCAN subscales, AIMS-2 hand/finger subscale, and FIOHA were not unidimensional scales. |
| Q36277361 | The Cochrane review of physiotherapy interventions for ankylosing spondylitis |
| Q51006503 | The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. |
| Q80161055 | The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases |
| Q35675593 | The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab |
| Q88164794 | The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis: Secondary Analyses From a Randomized Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regimen |
| Q87381959 | The L-arginine/asymmetric dimethylarginine ratio is improved by anti-tumor necrosis factor-α therapy in inflammatory arthropathies. Associations with aortic stiffness |
| Q35669636 | The Oslo experience with arthritis registries. |
| Q80697518 | The PTPN22 promoter polymorphism -1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material |
| Q94581340 | The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status |
| Q36790405 | The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study |
| Q64901257 | The association of hypertension with asymptomatic cardiovascular organ damage in rheumatoid arthritis. |
| Q48075422 | The burden of disease in rheumatoid arthritis |
| Q26766515 | The changing landscape of biosimilars in rheumatology |
| Q35953468 | The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study |
| Q50127607 | The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study |
| Q80607448 | The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study |
| Q50536568 | The comparison of magnetic resonance imaging and radiographs to assess structural progression over 5 years in hand osteoarthritis. |
| Q88308221 | The confidence of rheumatologists about switching to biosimilars for their patients |
| Q74046797 | The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up |
| Q100760424 | The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial |
| Q84474098 | The evidence for non-pharmacological therapy of hand and hip OA |
| Q35533763 | The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases |
| Q53489977 | The health-related quality of life of patients with epilepsy compared with angina pectoris, rheumatoid arthritis, asthma and chronic obstructive pulmonary disease. |
| Q48481162 | The impact of coping strategies on mental and physical well-being in patients with rheumatoid arthritis |
| Q50980183 | The impact of early rheumatoid arthritis on psychological distress. A comparison between 238 patients with RA and 116 matched controls. |
| Q50631890 | The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. |
| Q34027412 | The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis |
| Q79843915 | The population based studies in rheumatoid arthritis. A method of longterm followup studies |
| Q50913470 | The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. |
| Q51099678 | The relationship between psychological distress and traditional clinical variables: a 2 year prospective study of 216 patients with early rheumatoid arthritis. |
| Q51125841 | The relationship between self-reported pain and sociodemographic variables, anxiety, and depressive symptoms in rheumatoid arthritis. |
| Q51983212 | The responsiveness of health status measures in patients with rheumatoid arthritis: comparison of disease-specific and generic instruments. |
| Q45976305 | The responsiveness of joint counts, patient-reported measures and proposed composite scores in hand osteoarthritis: analyses from a placebo-controlled trial. |
| Q38068691 | The role of biosimilars in the treatment of rheumatic diseases |
| Q85842628 | The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study |
| Q34095599 | The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving st |
| Q35840842 | The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab |
| Q52006675 | The validity of self-reported diagnosis of rheumatoid arthritis: results from a population survey followed by clinical examinations. |
| Q37884937 | The value of isotype determination of serum antibodies against Chlamydia for the diagnosis of Chlamydia reactive arthritis |
| Q92451175 | Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study) |
| Q35554555 | Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study |
| Q45790066 | Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. |
| Q84141779 | Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial |
| Q47196067 | Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials |
| Q72891608 | Total and free plasma and total synovial fluid piroxicam concentrations: relationship to antiinflammatory effect in patients with reactive arthritis and other arthritides |
| Q33888275 | Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? |
| Q31975166 | Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity |
| Q91391399 | Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study |
| Q35740447 | Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire |
| Q37465349 | Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis |
| Q38690324 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
| Q42592295 | Treating rheumatoid arthritis |
| Q38476881 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force |
| Q34462557 | Treating rheumatoid arthritis to target: recommendations of an international task force |
| Q37465518 | Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force |
| Q28353468 | Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine |
| Q92734117 | Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration |
| Q34005055 | Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register |
| Q85777778 | Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic |
| Q90030533 | Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study |
| Q82354836 | Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study |
| Q34249182 | Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry |
| Q43522471 | Ultrasonographic assessment of osteophytes in 127 patients with hand osteoarthritis: exploring reliability and associations with MRI, radiographs and clinical joint findings |
| Q35953353 | Ultrasonographic measurement of the median nerve in patients with rheumatoid arthritis without symptoms or signs of carpal tunnel syndrome |
| Q81583852 | Ultrasonography shows increased cross-sectional area of the median nerve in patients with arthritis and carpal tunnel syndrome |
| Q82522937 | Ultrasonography shows significant improvement in wrist and ankle tenosynovitis in rheumatoid arthritis patients treated with adalimumab |
| Q37178957 | Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial |
| Q42278858 | Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study |
| Q50939048 | Ultrasound-detected inflammation predicts radiographic progression in hand osteoarthritis after 5 years. |
| Q40054563 | Ultrasound-detected osteophytes predict the development of radiographic and clinical features of hand osteoarthritis in the same finger joints 5 years later |
| Q27691388 | Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis |
| Q26995824 | Updating the OMERACT filter: core areas as a basis for defining core outcome sets |
| Q38201422 | Updating the OMERACT filter: discrimination and feasibility |
| Q38192493 | Updating the OMERACT filter: implications for patient-reported outcomes |
| Q27022415 | Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity |
| Q72344202 | Use of commercially produced elastic wrist orthoses in chronic arthritis: a controlled study |
| Q88162272 | Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study |
| Q45342350 | Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study |
| Q92403010 | Validation of the Intermittent and Constant Osteoarthritis Pain Questionnaire in Patients with Hand Osteoarthritis: Results from the Nor-Hand Study |
| Q45766371 | Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? |
| Q73497690 | Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density |
| Q76380328 | Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls |
| Q91006891 | What do we measure with 28-joint DAS in elderly patients? An explorative analysis in the NOR-DMARD study |
| Q37976245 | What is the clinical relevance of erosions and joint space narrowing in RA? |
| Q34531149 | Why do patients with chronic musculoskeletal disorders consult their primary care physicians? |
| Q51700591 | Work disability and health-related quality of life in males and females with psoriatic arthritis. |
| Q40360229 | Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register |
| Q64981913 | Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. |
| Q69044186 | [Antiphlogistics in musculoskeletal diseases] |
| Q67995070 | [Arthroses. Guidelines for diagnosis and treatment] |
| Q69677133 | [Auranofin (Ridaura). A new peroral agent containing gold used in the treatment of rheumatoid arthritis] |
| Q80210243 | [Bechterew disease--a consensus on diagnosis and treatment] |
| Q82678438 | [Clinical use of COX inhibitors--a consensus] |
| Q74632073 | [Cyclooxygenase-1 and cyclooxygenase-2--important for the clinicians?] |
| Q50615808 | [Development of standards by the Norwegian Society of Rheumatology. Control of disease modifying drugs] |
| Q71769268 | [Diagnostic evaluation of suspected reactive arthritis] |
| Q74241357 | [Differences in morbidity between the Eastern central city district and the suburban Western district of Oslo] |
| Q71125391 | [Disease-modifying drugs in rheumatoid arthritis. Duration of treatment and reasons for withdrawal] |
| Q79857603 | [Functional assessment in rehabilitation] |
| Q70991233 | [Immunomodulating drugs in rheumatic diseases in adults and children] |
| Q72537354 | [Methotrexate. Efficient, but not without hazards in rheumatoid arthritis] |
| Q73460359 | [Myalgia and high sedimentation rate in adults] |
| Q93585331 | [Non-steroidal anti-inflammatory agents in juvenile rheumatoid arthritis] |
| Q67995068 | [Rheumatoid arthritis and Bechterew's disease. Guidelines for diagnosis and treatment] |
| Q77933929 | [Rheumatoid arthritis] |
| Q68158167 | [Sulindac. Is it different from other non-steroidal anti-inflammatory agents?] |
| Q70554334 | [The handling of drugs for a clinical trial] |
| Q73358583 | [Vertebral fractures in osteoporosis--silent fractures of clinical importance] |
| nb | Tore K. Kvien | wikipedia |
Search more.